Two more studies show that GlaxoSmithKline (GSK) blockbuster diabetes drug Avandia has significant health risks. According to The Wall Street Journal "the Food and Drug Administration is considering whether Avandia’s use should be restricted."…
An interesting event happened yesterday in the form of an SEC Filing on Dendreon (NASDAQ:DNDN) that ran the stock. In a fed-filing from yesterday it was disclosed that BNP Paribas Arbitrage SA held 6,961,101…
Amgen (NASDAQ:AMGN) has a huge day ahead of it. The biotech giant is presenting data today on the appropriateuse of Erythropoiesis Stimulating Agents in Chronic RenalFailure patients to a joint meeting of U.S. Food…
Shares of Imclone Systems Inc. (NASDAQ:IMCL) are screaming higher this morning on it meeting its primary endpoint of increasing survival in its Phase III lung cancer studies. Imclone and partner Bristol-Myers Squibb (NYSE:BMY) showed…
All those "green" people out there may want to take into consideration the fact that biofuels are unlikely to have a significant affect on the need for oil, and government subsidies for biofuel projects…
Add to the list of reasons not to have open heart surgery the potential use of Bayer’s (BAY) Trasylol to control bleeding. According to The Wall Street Journal "two studies published in 2006 suggested…
Medical device market Cardica (CRDC) hit a all-time high last Wednesday as a group of surgeons "successfully used its automated system during coronary artery bypass operations." It was not hundreds of surgeons in various…
Boston Scientific (BSX) has been vexed by problems with its stents, one of its largest businesses. There have been several medical research reports which say that the drug coated stents that the company markets…
Hollis-Edent (HEPH) is a very small development-stage pharmaceutical company. It has no revenue as has lost about $7 million each of the last couple of years. The stock has been a world class dog…
Amgen (NASDAQ:AMGN) has seen a slight recovery of late, mostly on reports that the U.S. Senate is asking Centers for Medicaid and Medicare Services to reconsider the drastically cut reimbursement rates. Shares just last…
Bioheart Inc. has set its IPO terms and it will trade under the NASDAQ ticker "BHRT." BioHeart has set its IPO terms and plans to offer 3.575 million shares in a price range of…
Drug developer AtheroGenics (AGIX) said Wednesday its failed heart-drug candidate showed signs it may be effective as an oral anti-diabetic drug The company is currently recruiting patients for a Phase III clinical trial on…
Patients who swtich from Pfizer’s (PFE) monster selling drug cholesterol pill Lipitor to Merck’s (MRK) Zocor, now available in generic form are more likely to have a heart attack or die. According to Reuters:…
After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that "patients given drug-coated stents after an acute heart attack are nearly five times more likely to…
http://www.bloomberg.com/apps/news?pid=20601087&sid=ajZ2lVrqeb2I&refer=homeA study out fo Sweden may help the flagging fortunes of the stent businesses at Boston Scientific (BSX) and Johnsohn & Johnson (JNJ). Several pieces of research had indicated that drug-coated stents could cause…